title: To Live or to Die: Prosurvival Activity of PPARgamma in Cancers.
abstract: The role of PPARgamma in tumorigenesis is controversial. In this article, we review and analyze literature from the past decade that highlights the potential proneoplastic activity of PPARgamma. We discuss the following five aspects of the nuclear hormone receptor and its agonists: (1) relative expression of PPARgamma in human tumor versus normal tissues; (2) receptor-dependent proneoplastic effects; (3) impact of PPARgamma and its agonists on tumors in animal models; (4) clinical trials of thiazolidinediones (TZDs) in human malignancies; (5) TZDs as chemopreventive agents in epidemiology studies. The focus is placed on the most relevant in vivo animal models and human data. In vitro cell line studies are included only when the effects are shown to be dependent on the PPARgamma receptor.
authors.affiliation: Molecular Hematopathology Laboratory, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
authors.forename: Y Lynn
authors.initials: YL
authors.lastname: Wang
authors.forename: Qi
authors.initials: Q
authors.lastname: Miao
references.citation: Trends Endocrinol Metab. 2002 Mar;13(2):75-8
references.pmid: 11854022
references.citation: Nat Med. 2003 Oct;9(10):1265-6
references.pmid: 12960963
references.citation: Nat Med. 1998 Sep;4(9):1053-7
references.pmid: 9734399
references.citation: J Immunol. 2007 Apr 1;178(7):4039-50
references.pmid: 17371958
references.citation: J Neurochem. 2006 Apr;97(2):435-48
references.pmid: 16539667
references.citation: Br J Clin Pharmacol. 1998 Jan;45(1):31-5
references.pmid: 9489591
references.citation: Gastroenterology. 2003 Feb;124(2):361-7
references.pmid: 12557142
references.citation: J Clin Invest. 2003 Sep;112(6):945-55
references.pmid: 12975479
references.citation: Cancer Res. 2005 Mar 15;65(6):2251-9
references.pmid: 15781638
references.citation: Nat Med. 1998 Sep;4(9):1046-52
references.pmid: 9734398
references.citation: Am J Pathol. 2007 Feb;170(2):722-32
references.pmid: 17255338
references.citation: Lancet Oncol. 2003 Oct;4(10):605-15
references.pmid: 14554238
references.citation: Cancer Res. 2001 Jul 1;61(13):5307-10
references.pmid: 11431375
references.citation: J Biol Chem. 1995 Jun 2;270(22):12953-6
references.pmid: 7768881
references.citation: Cardiovasc Res. 2004 Apr 1;62(1):135-44
references.pmid: 15023560
references.citation: Cancer Res. 1999 Nov 15;59(22):5671-3
references.pmid: 10582681
references.citation: Cancer J. 2002 Sep-Oct;8(5):395-9
references.pmid: 12416897
references.citation: Biochem Biophys Res Commun. 2001 Sep 28;287(3):727-32
references.pmid: 11563856
references.citation: J Immunol. 2006 Sep 15;177(6):3737-45
references.pmid: 16951334
references.citation: Cell. 1995 Dec 1;83(5):813-9
references.pmid: 8521498
references.citation: N Engl J Med. 2007 Aug 30;357(9):844-6
references.pmid: 17687124
references.citation: Science. 2000 Aug 25;289(5483):1357-60
references.pmid: 10958784
references.citation: Neuroscience. 2005;130(3):685-96
references.pmid: 15590152
references.citation: Mol Cell. 1999 Jun;3(6):799-804
references.pmid: 10394368
references.citation: N Engl J Med. 2007 Jul 5;357(1):28-38
references.pmid: 17551159
references.citation: Oncogene. 2006 May 4;25(19):2736-47
references.pmid: 16314832
references.citation: J Biol Chem. 2001 Jul 6;276(27):25049-56
references.pmid: 11292834
references.citation: J Pharm Biomed Anal. 1985;3(5):483-7
references.pmid: 16867662
references.citation: Clin Cancer Res. 2005 Jun 1;11(11):4012-21
references.pmid: 15930335
references.citation: Int J Cancer. 2003 May 1;104(5):597-602
references.pmid: 12594814
references.citation: Prostate. 2002 May 1;51(2):108-16
references.pmid: 11948965
references.citation: Mol Pharmacol. 2008 Mar;73(3):709-17
references.pmid: 18055759
references.citation: Br J Cancer. 2000 Nov;83(10):1394-400
references.pmid: 11044367
references.citation: Nat Med. 1998 Sep;4(9):1058-61
references.pmid: 9734400
references.citation: Cancer Res. 2005 Jun 1;65(11):4769-74
references.pmid: 15930296
references.citation: N Engl J Med. 2007 Jun 14;356(24):2457-71
references.pmid: 17517853
references.citation: Mol Cell. 1998 Feb;1(3):465-70
references.pmid: 9660931
references.citation: Oncogene. 2004 Jan 8;23(1):100-8
references.pmid: 14712215
references.citation: Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1983-93
references.pmid: 16609007
references.citation: Clin Cancer Res. 2007 Jan 1;13(1):246-52
references.pmid: 17200362
references.citation: Clin Cancer Res. 2006 Nov 1;12(21):6444-51
references.pmid: 17085658
references.citation: Lab Invest. 2003 Dec;83(12):1715-21
references.pmid: 14691289
references.citation: Breast Cancer Res Treat. 2003 Jun;79(3):391-7
references.pmid: 12846423
references.citation: Am J Nephrol. 2003 Jul-Aug;23(4):267-76
references.pmid: 12840602
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13771-6
references.pmid: 12370429
references.citation: J Neurosci. 2004 Feb 11;24(6):1312-8
references.pmid: 14960602
references.citation: J Biol Chem. 2002 Aug 30;277(35):31781-8
references.pmid: 12082115
references.citation: Mol Endocrinol. 2002 Dec;16(12):2793-801
references.pmid: 12456800
references.citation: Cancer Res. 1999 Jun 1;59(11):2739-46
references.pmid: 10364000
references.citation: Nature. 2000 Jan 6;403(6765):103-8
references.pmid: 10638762
references.citation: Cancer Res. 2000 Nov 1;60(21):6201-7
references.pmid: 11085546
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1476-81
references.pmid: 17442990
references.citation: Eur J Neurosci. 2006 Sep;24(6):1653-63
references.pmid: 17004929
references.citation: J Neurochem. 2007 Apr;101(1):41-56
references.pmid: 17394460
references.citation: J Med Chem. 2000 Feb 24;43(4):527-50
references.pmid: 10691680
references.citation: J Biol Chem. 2005 Mar 11;280(10):9604-9
references.pmid: 15632188
references.citation: Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5
references.pmid: 10984506
references.citation: Korean J Gastroenterol. 2004 May;43(5):291-8
references.pmid: 15156115
references.citation: J Biol Chem. 2002 May 17;277(20):17830-5
references.pmid: 11884400
references.citation: J Clin Endocrinol Metab. 2005 Jul;90(7):3886-96
references.pmid: 15886257
references.citation: Br J Cancer. 2005 Jan 17;92(1):113-9
references.pmid: 15583697
references.citation: Br J Cancer. 2003 Oct 20;89(8):1409-12
references.pmid: 14562008
references.citation: FASEB J. 2002 Jul;16(9):1027-40
references.pmid: 12087064
references.citation: Gene. 1999 Jun 24;234(1):87-91
references.pmid: 10393242
references.citation: Cancer. 2004 Oct 1;101(7):1569-74
references.pmid: 15468186
references.citation: Front Biosci. 2008 Jan 01;13:1813-26
references.pmid: 17981670
references.citation: Am J Physiol Cell Physiol. 2005 Apr;288(4):C899-905
references.pmid: 15590897
references.citation: Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41
references.pmid: 8990192
references.citation: Genes Dev. 2004 Mar 1;18(5):528-40
references.pmid: 15037548
references.citation: Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11
references.pmid: 9671760
references.citation: Trends Biochem Sci. 1999 Feb;24(2):68-72
references.pmid: 10098401
references.citation: J Clin Endocrinol Metab. 2001 May;86(5):2170-7
references.pmid: 11344222
references.citation: Carcinogenesis. 2004 Sep;25(9):1747-55
references.pmid: 15073042
references.citation: Surgery. 2006 Dec;140(6):960-6; discussion 966-7
references.pmid: 17188145
references.citation: Eur J Pharmacol. 2008 Feb 2;580(1-2):80-6
references.pmid: 18054911
references.citation: J Med Chem. 1996 Feb 2;39(3):665-8
references.pmid: 8576907
references.citation: Int J Cancer. 2005 Sep 10;116(4):495-9
references.pmid: 15818612